Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeTIL-0255 in Advanced Gynecologic Malignancies
NCT05107739Phase 1Terminated
- Sponsor
- Nurix Therapeutics
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Prophylactic Vaccines, Tumor-Infiltrating Lymphocytes (TILs), Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of DeTIL-0255 in ovarian cancer, Cervical Cancer (CC) and endometrial cancer (EC) (4 arms), sponsored by Nurix Therapeutics. Primary endpoints: Incidence of treatment emergent adverse events at 24 Months, Incidence of all deaths at 24 Months and 6 more. Started Dec 2021; status: terminated.
02
Drugs
DeTIL-0255
03
Conditions
ovarian cancerCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05107739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107739.